Detail akcie Celcuity Rg online

Business Summary: Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Celcuity Inc revenues was not reported. Net loss increased 68% to $126.1M. Higher net loss reflects Interest Expense increase of 57% to $11M (expense), Research & Development - Balancing value increase of 2% to $69.2M (expense), General & Administrative - Balancing v increase of 30% to $5.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.96 to -$2.82.